HRP20221338T1 - Primjena totarola i farmaceutski pripravak koji sadrži totarol - Google Patents
Primjena totarola i farmaceutski pripravak koji sadrži totarol Download PDFInfo
- Publication number
- HRP20221338T1 HRP20221338T1 HRP20221338TT HRP20221338T HRP20221338T1 HR P20221338 T1 HRP20221338 T1 HR P20221338T1 HR P20221338T T HRP20221338T T HR P20221338TT HR P20221338 T HRP20221338 T HR P20221338T HR P20221338 T1 HRP20221338 T1 HR P20221338T1
- Authority
- HR
- Croatia
- Prior art keywords
- totarol
- parts
- inflammation
- treatment
- mass
- Prior art date
Links
- CKZZREIPBTYJEQ-UHFFFAOYSA-N Totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(C)C=C2 CKZZREIPBTYJEQ-UHFFFAOYSA-N 0.000 title claims 4
- ZRVDANDJSTYELM-FXAWDEMLSA-N totarol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C(C(C)C)=C(O)C=C1 ZRVDANDJSTYELM-FXAWDEMLSA-N 0.000 title claims 4
- 229940074347 totarol Drugs 0.000 title claims 4
- ZRVDANDJSTYELM-UHFFFAOYSA-N trans-totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(O)C=C2 ZRVDANDJSTYELM-UHFFFAOYSA-N 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims 2
- 208000037009 Vaginitis bacterial Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (2)
1. Totarol za upotrebu u liječenju upala vaginalne sluznice bakterijskog porijekla, za ublažavanje simptoma u takvom liječenju i za profilaksu i prevenciju recidiva takvih upala, naznačen time što se odnosi na anaerobnu bakterijsku vaginozu (BV) i aerobni vaginitis (AV).
2. Farmaceutski pripravak za upotrebu u liječenju upala vaginalne sluznice bakterijskog porijekla, za ublažavanje simptoma u takvom liječenju i za profilaksu i prevenciju recidiva takvih upala, koji sadrži od 75 do 95 masenih dijelova derivata celuloze, poželjno metilceluloze, od 0,5 do 5 masenih dijelova mliječne kiseline, od 0,5 do 5 masenih dijelova bazičnog polimera, poželjno akrilnog polimera, najpoželjnije kopolimera metakrilne kiseline i etil akrilata, ili kitozana ili polivinilpirolidona ili njihovih smjesa, pri čemu je stehiometrijski omjer mliječne kiseline prema bazičnom polimeru u rasponu od 1:1 do 8:1, naznačen time što kao djelatnu tvar sadrži totarol u količini od 0,001 do 5 masenih dijelova.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL422140A PL236429B1 (pl) | 2017-07-06 | 2017-07-06 | Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym |
| EP18765765.5A EP3648751B1 (en) | 2017-07-06 | 2018-07-04 | Application of totarol and pharmaceutical composition containing totarol |
| PCT/PL2018/000066 WO2019009739A1 (en) | 2017-07-06 | 2018-07-04 | APPLICATION OF TOTAROL AND PHARMACEUTICAL COMPOSITION CONTAINING TOTAROL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221338T1 true HRP20221338T1 (hr) | 2022-12-23 |
Family
ID=63518002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221338TT HRP20221338T1 (hr) | 2017-07-06 | 2018-07-04 | Primjena totarola i farmaceutski pripravak koji sadrži totarol |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11534412B2 (hr) |
| EP (1) | EP3648751B1 (hr) |
| KR (1) | KR20200024921A (hr) |
| BR (1) | BR112019027839A2 (hr) |
| CA (1) | CA3066602C (hr) |
| CL (1) | CL2019003720A1 (hr) |
| DK (1) | DK3648751T3 (hr) |
| ES (1) | ES2929646T3 (hr) |
| HR (1) | HRP20221338T1 (hr) |
| HU (1) | HUE060300T2 (hr) |
| IL (1) | IL271875B2 (hr) |
| LT (1) | LT3648751T (hr) |
| MA (2) | MA50979B1 (hr) |
| PL (1) | PL236429B1 (hr) |
| PT (1) | PT3648751T (hr) |
| RS (1) | RS63728B1 (hr) |
| SI (1) | SI3648751T1 (hr) |
| UA (1) | UA126031C2 (hr) |
| WO (1) | WO2019009739A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114948891A (zh) * | 2021-06-07 | 2022-08-30 | 南通联亚药业股份有限公司 | 药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL201869A1 (pl) | 1977-10-29 | 1979-05-21 | Inst Przemyslu Organiczego | Sposob wytwarzania masy kablowej odpornej na dzialanie termitow |
| PL107491B1 (pl) | 1977-10-29 | 1980-02-29 | Przemyslowy Instytut Automatyk | Czujnik dwustrunowy do pomiaru malych przesuniec |
| JP2700071B2 (ja) | 1988-06-10 | 1998-01-19 | 株式会社資生堂 | 抗菌剤及びそれを用いた皮膚外用剤、口腔用組成物 |
| PL166898B1 (pl) | 1992-02-13 | 1995-06-30 | Akad Medyczna | Sposób wytwarzania kompleksu metylocelulozy z kwasem mlekowym |
| US6534548B1 (en) * | 2001-10-02 | 2003-03-18 | Kimberly-Clark Worldwide, Inc. | Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria |
| PL194437B1 (pl) | 2002-06-05 | 2007-05-31 | Akademia Medyczna Im Piastow S | Sposób wytwarzania kompleksu na bazie kwasu mlekowego |
| NZ530834A (en) | 2004-01-28 | 2007-06-29 | Owen John Catchpole | Near-critical extraction of totarol and/or a product containing totarol |
| US20090312279A1 (en) * | 2005-12-23 | 2009-12-17 | Sterilex Technologies, Llc | Antimicrobial compositions |
| EP1925302A1 (en) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression |
| EP1925301A1 (en) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders |
| JP5471335B2 (ja) * | 2009-11-17 | 2014-04-16 | ライオン株式会社 | 口腔バイオフィルム殺菌剤 |
| CN103974617B (zh) * | 2011-12-15 | 2015-11-25 | 高露洁-棕榄公司 | 百里酚和桃拓酚抗菌组合物 |
| WO2014137231A2 (en) | 2013-03-07 | 2014-09-12 | T2G Biotechnology Limited | Totarol extract formulations and uses thereof |
| DE102013108870A1 (de) * | 2013-08-16 | 2015-02-19 | Aimecs Gmbh | Mittel zur Reinigung und zum Schutz von technischen Oberflächen |
| CN104027260A (zh) | 2014-06-20 | 2014-09-10 | 广州薇美姿个人护理用品有限公司 | 一种含有桃柘酚的口腔护理用品 |
| CN104688810A (zh) * | 2014-12-29 | 2015-06-10 | 昆明皕凯科技有限公司 | 一种基于天然植物原料的抗菌组合物及其应用 |
| CN106581687A (zh) * | 2016-12-22 | 2017-04-26 | 吉林大学 | 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法 |
-
2017
- 2017-07-06 PL PL422140A patent/PL236429B1/pl unknown
-
2018
- 2018-07-04 RS RS20221013A patent/RS63728B1/sr unknown
- 2018-07-04 CA CA3066602A patent/CA3066602C/en active Active
- 2018-07-04 PT PT187657655T patent/PT3648751T/pt unknown
- 2018-07-04 MA MA50979A patent/MA50979B1/fr unknown
- 2018-07-04 KR KR1020207003488A patent/KR20200024921A/ko not_active Application Discontinuation
- 2018-07-04 SI SI201830794T patent/SI3648751T1/sl unknown
- 2018-07-04 UA UAA201911771A patent/UA126031C2/uk unknown
- 2018-07-04 BR BR112019027839-7A patent/BR112019027839A2/pt unknown
- 2018-07-04 LT LTEPPCT/PL2018/000066T patent/LT3648751T/lt unknown
- 2018-07-04 US US16/629,005 patent/US11534412B2/en active Active
- 2018-07-04 ES ES18765765T patent/ES2929646T3/es active Active
- 2018-07-04 HR HRP20221338TT patent/HRP20221338T1/hr unknown
- 2018-07-04 DK DK18765765.5T patent/DK3648751T3/da active
- 2018-07-04 EP EP18765765.5A patent/EP3648751B1/en active Active
- 2018-07-04 WO PCT/PL2018/000066 patent/WO2019009739A1/en unknown
- 2018-07-04 MA MA050980A patent/MA50980A/fr unknown
- 2018-07-04 HU HUE18765765A patent/HUE060300T2/hu unknown
-
2019
- 2019-12-18 CL CL2019003720A patent/CL2019003720A1/es unknown
-
2020
- 2020-01-06 IL IL271875A patent/IL271875B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020104832A (ru) | 2021-08-06 |
| HUE060300T2 (hu) | 2023-02-28 |
| CA3066602A1 (en) | 2019-01-10 |
| CL2019003720A1 (es) | 2020-05-22 |
| SI3648751T1 (sl) | 2023-03-31 |
| UA126031C2 (uk) | 2022-08-03 |
| PL236429B1 (pl) | 2021-01-11 |
| US11534412B2 (en) | 2022-12-27 |
| CA3066602C (en) | 2024-01-02 |
| PT3648751T (pt) | 2022-10-20 |
| MA50979A (fr) | 2020-10-14 |
| MA50980A (fr) | 2020-10-14 |
| RS63728B1 (sr) | 2022-12-30 |
| WO2019009739A1 (en) | 2019-01-10 |
| MA50979B1 (fr) | 2022-11-30 |
| EP3648751B1 (en) | 2022-09-28 |
| WO2019009739A4 (en) | 2019-02-28 |
| ES2929646T3 (es) | 2022-12-01 |
| DK3648751T3 (da) | 2022-11-21 |
| IL271875A (en) | 2020-02-27 |
| LT3648751T (lt) | 2022-12-12 |
| EP3648751A1 (en) | 2020-05-13 |
| BR112019027839A2 (pt) | 2020-07-07 |
| IL271875B2 (en) | 2023-02-01 |
| US20200289429A1 (en) | 2020-09-17 |
| IL271875B (en) | 2022-10-01 |
| KR20200024921A (ko) | 2020-03-09 |
| RU2020104832A3 (hr) | 2021-10-08 |
| PL422140A1 (pl) | 2019-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| JP2015038135A5 (hr) | ||
| PH12017502326A1 (en) | Orodispersible dosage unit containing an estetrol component | |
| RS52922B (en) | PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| ES2572277T3 (es) | Composiciones fijadoras para el cabello | |
| NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| MX2019015733A (es) | Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. | |
| HRP20221338T1 (hr) | Primjena totarola i farmaceutski pripravak koji sadrži totarol | |
| WO2015086838A3 (en) | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| FI3509595T3 (fi) | Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita | |
| MX2013012557A (es) | Composicion vaginal a base de poliglucosidos de alquilo. | |
| PE20231946A1 (es) | Formulacion solida | |
| RS54602B1 (en) | LOCAL TREATMENT COMPOSITION | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
| BRPI1010987B8 (pt) | composições de dosagem sólida de liberação controlada contendo ibuprofeno | |
| CO2021014253A2 (es) | Formulación de tableta vaginal |